We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Clinical Pipeline

Galapagos is progressing one of the largest pipelines in biotech, with a broad range of disease areas being explored in Phase 2 and Phase 3 with filgotinib, Phase 3 with '1690 and Phase 2 with '1205 in IPF, multiple Phase 1 and Phase 2 studies with other clinical programs, and >20 discovery programs.

Clinical Pipeline October 2019